title: Effect of high-potency statins on HbA1c in patients with or without diabetes mellitus.
abstract: BACKGROUND
  The increased risk of new-onset diabetes with statin use, including high-potency statins, is well known. However, the effects of high-potency statins on HbA1c are unclear. A retrospective cohort study was conducted to examine the effect of high-potency statins on HbA1c in patients with or without diabetes. The study enrolled new statin users identified via the electronic healthcare database of the general hospital in Japan.
  
  
  METHODS
  Following identification of all individuals (n = 4,672) who had been prescribed a lipid lowering drug at least once between January 1, 2010 and July 31, 2014, new statin users were selected (n = 1,136). Patients were excluded if they had been prescribed treatment with a statin within the preceding 6-month period. HbA1c levels before and during high-potency statin treatment were compared using the dependent t-test. In addition, the hazard ratio for the incidence of diabetes with high-potency statin treatment was estimated, using low-potency statins as a reference.
  
  
  RESULTS
  In patients with diabetes (n = 153), mean HbA1c (%) levels significantly increased by 0.4 % after high-potency statin use (7.57 ± 1.58; p = 0.0002) compared to baseline (7.18 ± 1.37). Similarly, HbA1c (%) levels significantly increased from 5.78 ± 0.38 to 5.92 ± 0.45 (p < 0.0001) after high-potency statin use in patients without diabetes (n = 165). Furthermore, a trend toward an increase in HbA1c was found for all of the high-potency statins irrespective of a history of diabetes.
  
  
  CONCLUSIONS
  The use of high-potency statins may increase HbA1c levels in patients with or without diabetes.
authors.affiliation: Department of Clinical Pharmacy, The Nihon University School of Pharmacy, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555 Japan.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Ooba
authors.affiliation: Department of Clinical Pharmacy, The Nihon University School of Pharmacy, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555 Japan.
authors.forename: Shoutarou
authors.initials: S
authors.lastname: Tanaka
authors.affiliation: Department of Clinical Pharmacy, The Nihon University School of Pharmacy, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555 Japan.
authors.forename: Yu
authors.initials: Y
authors.lastname: Yasukawa
authors.affiliation: Department of Clinical Pharmacy, The Nihon University School of Pharmacy, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555 Japan.
authors.forename: Nariyasu
authors.initials: N
authors.lastname: Yoshino
authors.affiliation: Department of Pharmacotherapy, The Nihon University School of Pharmacy, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555 Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hayashi
authors.affiliation: Department of Pharmaceutical Regulatory Science, The Nihon University School of Pharmacy, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555 Japan.
authors.forename: Shinji
authors.initials: S
authors.lastname: Hidaka
authors.affiliation: The Hitachinaka General Hospital, 20-1 Ishikawachou, Hitachinaka-shi, Ibaraki 312-0057 Japan.
authors.forename: Toshiichi
authors.initials: T
authors.lastname: Seki
authors.affiliation: Department of Clinical Pharmacy, The Nihon University School of Pharmacy, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555 Japan.
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Fukuoka
keywords: Hemoglobin A1c; High-potency statin; New-user design